Evaluation on the safety and immunogenicity of a new measles-mumps-rubella vaccine(MMR) with a licensed vaccines

To evaluate the safety and immunogenicity of a new measles-mumps-rubella(Hu MMR) vaccine in comparison with licensed MMR(Merck),monovalent measles vaccine,monovalent mumps vaccine and monovalent rubella vaccine.1188 healthy children between 8 and 18 months were enrolled.They were randomized into four groups to receive different vaccines.Except candidate vaccine group had higher fever rates than that of Merck group(8.60% and 2.00%,respectively),the incidences of all other solicited local and general symptoms were comparable between the two groups.Seroconversion rate of measles antibody in trial group was higher than that of Merck MMR vaccine group(99.5% vs 94.6%).GMT of measles antibody in trial group was also higher than that of measles vaccine group.Seroconversion rates of mumps and rubella antibodies had no significant difference between trial group and Merck vaccine group.In conclusion,the new MMR vaccine demonstrated satisfactory immunogenicity and safety profiles as good as the Merck MMR vaccine.